Abstract
Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 31-36 |
| Number of pages | 6 |
| Journal | Clinical Journal of Sport Medicine |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- autologous plasma
- muscle injury
- platelet-enriched plasma
- platelet-rich plasma
ASJC Scopus subject areas
- Medicine(all)
Cite this
Platelet-enriched plasma and muscle strain injuries : Challenges imposed by the burden of proof. / Hamilton, Bruce H.; Best, Thomas.
In: Clinical Journal of Sport Medicine, Vol. 21, No. 1, 01.01.2011, p. 31-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Platelet-enriched plasma and muscle strain injuries
T2 - Challenges imposed by the burden of proof
AU - Hamilton, Bruce H.
AU - Best, Thomas
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.
AB - Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.
KW - autologous plasma
KW - muscle injury
KW - platelet-enriched plasma
KW - platelet-rich plasma
UR - http://www.scopus.com/inward/record.url?scp=78651395469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651395469&partnerID=8YFLogxK
U2 - 10.1097/JSM.0b013e318205a658
DO - 10.1097/JSM.0b013e318205a658
M3 - Article
C2 - 21200168
AN - SCOPUS:78651395469
VL - 21
SP - 31
EP - 36
JO - Clinical Journal of Sport Medicine
JF - Clinical Journal of Sport Medicine
SN - 1050-642X
IS - 1
ER -